was noted to be highly associated with this hypersensitivity reaction. The purpose of this study was to evaluate the effectiveness of prospective HLA-B*5701 screening to avoid these reactions.

**STUDY POPULATION.** A total of 1956 HIV-infected patients from 19 countries who had not previously received abacavir were enrolled.

**METHODS.** Individual patients were randomly assigned to undergo prospective HLA-B*5701 screening, with exclusion of previously known HLA-B*5701 positive patients from abacavir treatment, or to undergo a standard approach of abacavir use without screening. All subjects who started abacavir were observed for 6 weeks, the time frame in which a large majority of hypersensitivity reactions occur. The clinical diagnosis of hypersensitivity reaction to abacavir was assessed further by epicutaneous patch testing.

**RESULTS.** The prevalence of HLA-B*5701 was 5.76% (109 of 1956 subjects) of the subjects assigned to receive abacavir. Seventy-two percent were men, 84% were white, and 18% had not received antiretroviral therapy previously. Screening effectively eliminated patch-test–confirmed hypersensitivity. None of the subjects in the prospectively screened group had reactions, compared with 2.7% in the control group. This yielded a negative predictive value of 100% and a positive predictive value of 47.9%. Hypersensitivity reactions to antiretroviral therapy were clinically diagnosed in 93 patients, with a significantly lower incidence in the prospectively screened group (3.4%) than in the control group (7.8%) \( (P < .001) \).

**CONCLUSIONS.** HLA-B*5701 screening dramatically reduced the risk of immunologically confirmed hypersensitivity to abacavir. This pharmacogenetic test is useful for reducing the incidence of immunologically mediated hypersensitivity reactions to abacavir.

**REVIEWER COMMENTS.** This expansive study demonstrated the clinical usefulness of pharmacogenomics testing for immunologically mediated hypersensitivity to a particular drug. This is the first such demonstration for reactions to antiretroviral agents. A major limitation in the use of abacavir has been the concern for a severe hypersensitivity reaction. The availability of this inexpensive test (approximately $80 at our institution) substantially reduces that potential and allows antiretroviral therapy selection to be based on the drug’s merit as an effective antiretroviral agent. A unique feature of hypersensitivity to this particular drug is that it is a true T-cell–mediated reaction. Patch testing has been used for many decades to identify offending contact hypersensitivity allergens (eg, nickel). The search for additional biomarkers that would reflect a potential for adverse reactions to other drugs is ongoing. This type of study leads the way in demonstrating clinical effectiveness of such an approach.

**REFERENCES.**

**RESULTS.** Histology of positive patch tests showed an influx of mononuclear cells (predominantly CD4\(^+\), CD25\(^+\), and CD45RO\(^+\)). This influx was detected earlier in the pollen patch-test reactions compared with the immune response to nickel. A biphasic cytokine response could be detected in skin samples from the pollen patch test: interleukin 5 dominated in the early phase, and interferon \( \gamma \) dominated in the late phase. The nickel patch test was continuously dominated by interferon \( \gamma \).

**CONCLUSIONS.** Pollen grains induce eczematous reactions in susceptible individuals. This reaction seems clinically and immunohistochemically similar to the contact hypersensitivity reaction to nickel but follows a faster kinetic and a biphasic course: T-helper 2 and immunoglobulin E in the early (24-hour) phase and T-helper 1 predominance in the late (96-hour) phase.

**REVIEWER COMMENTS.** This article highlights the importance of understanding that type 1 allergy-inducing antigens...
such as pollens can exacerbate atopic eczema in susceptible individuals. Physicians should remember to discuss this with their atopic patients before the start of pollen season.

URL: www.pediatrics.org/cgi/doi/10.1542/peds.2008-2139MM

Jennifer M. Maloney, MD
New York, NY

Severe Atopic Dermatitis Is Associated With a High Burden of Environmental Staphylococcus aureus

PURPOSE OF THE STUDY. It has been established that Staphylococcus aureus worsens atopic dermatitis (AD) by a variety of mechanisms. The purpose of this study was to quantify S aureus burden in the homes of participants with AD of varying severity.

STUDY POPULATION. There were 62 volunteers aged 1 to 40 years. Participants were categorized as having mild (n = 18), moderate (n = 14), severe (n = 15), or no (n = 15) AD.

METHODS. Participants completed questionnaires about their asthma, allergies, and home environment. Patients with AD completed a Lung-Browder diagram, documenting the area and intensity of erythema, excoriation, papulation, and lichenification. From these diagrams, AD severity was calculated by using the Eczema Area and Severity Index (EASI). Subjects collected dust samples from their bed, the floor next to their bed, and the home vacuum bag and sent them to the laboratory for analysis. S aureus DNA was extracted, and quantitative reverse-transcription polymerase chain reaction for the femB gene (an S aureus-specific genomic marker) was performed. Data were log-transformed and then analyzed with analysis of variance, student’s t test, and Spearman’s r.

RESULTS. Bed dust yielded the highest S aureus concentrations. Participants with severe AD had significantly more S aureus DNA (14.67 pg/mg dust) in bed dust than those with moderate (0.41 pg/mg dust; P < .0001), mild (1.42 pg/mg; P = .0051), and no (0.09 pg/mg; P < .0001) AD. The concentration of S aureus DNA in bed dust strongly correlated with EASI scores. Similar patterns were observed for dust from bedroom floors for both DNA concentrations and EASI scores. The quantity of S aureus DNA from the vacuum samples was significantly higher in participants with severe AD versus moderate, mild, and no AD. However, there was no correlation between EASI scores and concentrations of S aureus DNA from vacuum dust samples.

CONCLUSIONS. S aureus is ubiquitous and was detected in dust samples from almost all homes regardless of disease state. However, house dust from participants with severe AD contained the most S aureus DNA. The correlation between S aureus DNA levels and AD severity is driven by proximity to the patient, as shown by the fact that the bed and bedroom floors from the patients with AD yielded the highest levels of S aureus DNA. In the home and especially the bedroom, higher levels of S aureus may contribute to disease severity and persistence in patients with AD.

URL: www.pediatrics.org/cgi/doi/10.1542/peds.2008-2139NN

Mariah M. Pieretti, MD
Scott H. Sicherer, MD, FAAP
New York, NY

IgE Food Sensitization in Infants With Eczema Attending a Dermatology Clinic

PURPOSE OF THE STUDY. Because community-based studies, which report immunoglobulin E food sensitization (IgE-FS) in >80% of infants with moderate atopic eczema, may be influenced by referral bias, the researchers assessed the prevalence of IgE-FS in a cohort of infants with moderate atopic eczema who were attending a dermatology department clinic.

STUDY POPULATION. Consecutive infants (n = 51 [39 boys]; median age: 34 weeks [range: 20–51 weeks]) with moderate atopic eczema severity were studied prospectively.

METHODS. Clinical history and eczema severity were documented. IgE-FS was assessed by the skin-prick test (SPT) (n = 51) and food-specific serum IgE antibody levels (CAP-FEIA test; n = 41). IgE-FS was diagnosed if the SPT or CAP-FEIA level exceeded the >95% predictive reference cutoff for positive food-challenge results.
Pollen Grains Induce a Rapid and Biphasic Eczematous Immune Response in Atopic Eczema Patients

Jennifer M. Maloney

*Pediatrics* 2008;122;S195

DOI: 10.1542/peds.2008-2139MM

---

Updated Information & Services

including high resolution figures, can be found at:

/content/122/Supplement_4/S195

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Dermatology
/cgi/collection/dermatology_sub

Allergy/Immunology
/cgi/collection/allergy:immunology_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

/site/misc/Permissions.xhtml

Reprints

Information about ordering reprints can be found online:

/site/misc/reprints.xhtml

---

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2008 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Pollen Grains Induce a Rapid and Biphasic Eczematous Immune Response in Atopic Eczema Patients
Jennifer M. Maloney
Pediatrics 2008;122;S195
DOI: 10.1542/peds.2008-2139MM

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/122/Supplement_4/S195